Efficacy and Safety of Targeted Intramyocardial Delivery of Auto CD34+ Stem Cells for Improving Exercise Capacity in Subjects With Refractory Angina
Trial ID or NCT#
The purpose of the study is to assess the safety and efficacy of targeted intramyocardial delivery of Auto-CD34+ cells for increasing exercise time and amelioration of anginal symptoms in subjects with refractory angina and chronic myocardial ischemia.
A Prospective, Randomized, Double-blinded, Active-control and Unblinded Standard of Care (SOC) Controlled Study to Determine the Efficacy and Safety of Targeted Intramyocardial Delivery of Autologous CD34+ Cells (Auto-CD34+ Cells) for Increasing Exercise Capacity During Standardized Exercise Testing in Subjects With Refractory Angina Pectoris and Chronic Myocardial Ischemia
- - Male or female participants who are 21 to 80 years of age at the time of signing the informed consent. - Participants with Canadian Cardiovascular Society (CCS) class III or IV chronic refractory angina. - Participants without control of their angina symptoms in spite of maximal tolerated doses of anti-angina drugs. Participants must be on optimal therapy for their angina and must have been on a stable anti-anginal medication regimen for at least 4 weeks before signing the informed consent form. - Participants with obstructive coronary disease unsuitable for conventional revascularization due to unsuitable anatomy or comorbidity as determined at the site and confirmed by an independent adjudication committee. - Participants must have evidence of inducible myocardial ischemia. - Participants must experience angina episodes. - Participants must be able to complete 2 exercise tolerance tests on the treadmill within 3 weeks of randomization. - If female of childbearing potential, subject must not be pregnant and agree to employ adequate birth control measures for the duration of the study. Main
- - Cardiovascular hospitalization within 60 days prior to potential study enrollment. Participant has had a successful or partially successful coronary artery bypass graft (CABG) within 6 months or PCTA within 60 days of potential study enrollment. - Participant has had a placement of a bi-ventricular pacemaker for cardiac resynchronization therapy (CRT) for heart failure within 180 days of potential study enrollment. - Participant has documented stroke or transient ischemic attacks (TIAs) within 60 days of potential study enrollment. - Participant has a history of moderate to severe aortic stenosis; or severe aortic insufficiency; or severe mitral stenosis; or severe mitral insufficiency. - Participant has a prosthetic aortic valve or a mechanical mitral valve replacement. - Participant has severe co-morbidity associated with a reduction in life expectancy to less than 3 years as a result of chronic medical illnesses. - Participants with cancer are excluded with the following exceptions: - Subjects with in-situ non-melanoma skin cancer or in-situ cervical cancer are not excluded. - Participants that have been cancer free for >= 5 years as determined by their oncologist are not excluded. Subjects with a prior history of stem cell transplant for cancer are excluded no matter how long they have been cancer-free. - Participants with a history of leukemia or other bone marrow disease. - Participant has sickle cell disease or sickle cell trait. - Participants with proliferative retinopathy. - Participants with Hb A1c > 9%. - Participant has platelet counts >10% above the upper limit of normal (ULN) or platelet counts < 70,000. - Participant has a hematocrit < 30% prior to potential study enrollment. - Participant has a serum creatinine > 2.5 mg/dL prior to potential study enrollment. - Participant tests positive for HIV, hepatitis B, or hepatitis C, or is on chronic immunosuppressive medications, or has had a previous stem cell transplant. - Participant has a known contraindication to Neupogen (filgrastim) or G-CSF. - Participant was previously enrolled in an active treatment group of cell therapy trials for cardiovascular disease including any phase of CD34+ stem cell trials. - Left ventricular (LV) thickness of < 7 mm in the target areas of injection as measured by during a 2-D echocardiogram (ECHO). - Atrial fibrillation, atrial flutter, or other uncontrolled arrhythmias that would prohibit accurate electromechanical mapping and NOGA-guided intramyocardial injection. - Bleeding diathesis with an INR > 1.8 when not receiving anti-thrombotic therapy. - Hepatic dysfunction as evidenced by elevated AST or ALT levels > 2.5 x ULN. - Any previous transplant requiring immunosuppression. - Disease state requiring chronic immunosuppression.
Contact us to find out if this trial is right for you.